Oxacillin
Bactocill, Oxacillin (oxacillin) is a small molecule pharmaceutical. Oxacillin was first approved as Prostaphlin on 1982-01-01. It is used to treat bacterial endocarditis, bacterial infections, bacterial meningitis, cellulitis, and osteomyelitis amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Bactocill, Oxacillin (discontinued: Bactocill, Oxacillin, Prostaphlin)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| oxacillin | ANDA | 2025-08-13 |
| oxacillin oxacillin | ANDA | 2025-08-13 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J2700 | Injection, oxacillin sodium, up to 250 mg |
Clinical
Clinical Trials
58 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | 1 | 3 | 3 | 6 | 13 |
| Bacteremia | D016470 | EFO_0003033 | R78.81 | — | 2 | 3 | 4 | 3 | 12 |
| Staphylococcal infections | D013203 | — | A49.01 | — | 1 | 3 | 4 | 3 | 11 |
| Communicable diseases | D003141 | — | — | — | 1 | 2 | 3 | 2 | 8 |
| Cellulitis | D002481 | EFO_0003035 | L03.90 | — | 2 | 1 | 4 | 1 | 8 |
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | 1 | 1 | 2 | — | 5 |
| Wound infection | D014946 | — | — | — | 2 | — | 2 | — | 4 |
| Abscess | D000038 | EFO_0003030 | — | — | 2 | — | 2 | — | 4 |
| Infectious skin diseases | D012874 | — | — | — | — | 2 | 1 | — | 3 |
| Infectious arthritis | D001170 | EFO_1001351 | M00 | — | 1 | — | 2 | — | 3 |
Show 19 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bacterial infections | D001424 | — | A49 | 1 | — | 2 | — | 2 | 5 |
| Gram-positive bacterial infections | D016908 | — | — | — | 3 | 1 | — | — | 4 |
| Methicillin-resistant staphylococcus aureus | D055624 | — | — | — | — | 2 | — | — | 2 |
| Mastitis | D008413 | EFO_1001034 | N61 | — | 1 | 1 | — | 1 | 2 |
| Staphylococcal skin infections | D013207 | EFO_1001849 | L00 | — | — | 1 | — | — | 1 |
| Bacterial skin diseases | D017192 | — | — | — | — | 1 | — | — | 1 |
| Sepsis | D018805 | EFO_0001420 | A41.9 | — | — | 1 | — | — | 1 |
| Disease susceptibility | D004198 | — | — | — | — | 1 | — | — | 1 |
| Staphylococcus | D013210 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
| Drug interactions | D004347 | — | — | 2 | — | — | — | — | 2 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | — | — | — | 1 | 2 |
| Chronic renal insufficiency | D051436 | — | N18 | 1 | — | — | — | — | 1 |
| Bacterial vaginosis | D016585 | EFO_0003932 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal dialysis | D006435 | EFO_0010690 | Z99.2 | — | — | — | — | 1 | 1 |
| Neutropenia | D009503 | — | D70 | — | — | — | — | 1 | 1 |
| Neoplasms | D009369 | — | C80 | — | — | — | — | 1 | 1 |
| Fever | D005334 | — | R50.9 | — | — | — | — | 1 | 1 |
| Febrile neutropenia | D064147 | — | — | — | — | — | — | 1 | 1 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | — | — | 1 | 1 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | — | — | 1 | 1 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | — | — | 1 | 1 |
| Surgical wound infection | D013530 | — | — | — | — | — | — | 1 | 1 |
| Respiratory tract infections | D012141 | — | J06.9 | — | — | — | — | 1 | 1 |
Show 8 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Oxacillin |
| INN | oxacillin |
| Description | Oxacillin is a penicillin antibiotic carrying a 5-methyl-3-phenylisoxazole-4-carboxamide group at position 6beta. It has a role as an antibacterial agent and an antibacterial drug. It is a conjugate acid of an oxacillin(1-). |
| Classification | Small molecule |
| Drug class | penicillins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1onc(-c2ccccc2)c1C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12 |
Identifiers
| PDB | — |
| CAS-ID | 66-79-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL819 |
| ChEBI ID | 7809 |
| PubChem CID | 6196 |
| DrugBank | DB00713 |
| UNII ID | UH95VD7V76 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Oxacillin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 19,065 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,668 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use